L-Carnitine Found to Improve Heart Attack Outcomes
Significant improvements seen in all-cause mortality, ventricular arrhythmias, and angina
FRIDAY, April 26 (HealthDay News) -- L-carnitine significantly improves patient outcomes following heart attack, according to a review published online April 17 in the Mayo Clinic Proceedings.
James J. DiNicolantonio, Pharm.D., from Wegmans Pharmacy in Ithaca, N.Y., and colleagues conducted a systematic literature review and meta-analysis of 13 controlled trials (3,629 participants) that evaluated the effects of L-carnitine versus placebo or control on mortality, ventricular arrhythmias (VAs), angina, heart failure, and reinfarction.
The researchers found that, compared to placebo or control, L-carnitine was associated with a significant 27 percent reduction in all-cause mortality (odds ratio, 0.73; risk ratio [RR], 0.78; P = 0.05), a highly significant 65 percent reduction in VAs (RR, 0.35), and a significant 40 percent reduction in the development of angina (RR, 0.60). There was no reduction in the development of heart failure (RR, 0.85; P = 0.21) or myocardial reinfarction (RR, 0.78; P = 0.45).
"Further study with large randomized controlled trials of this inexpensive and safe therapy in the modern era is warranted," the authors write.
Abstract (http://www.mayoclinicproceedings.org/article/S0025-6196(13)00127-4/abstract )Full Text (subscription or payment may be required) (http://www.mayoclinicproceedings.org/article/S0025-6196(13)00127-4/fulltext )